help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Maghnie, M.
Right arrow Articles by Ghigo, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Maghnie, M.
Right arrow Articles by Ghigo, E.
The Journal of Clinical Endocrinology & Metabolism Vol. 87, No. 6 2740-2744
Copyright © 2002 by The Endocrine Society


Endocrine Care

GHRH Plus Arginine in the Diagnosis of Acquired GH Deficiency of Childhood-Onset

Mohamad Maghnie, Francesco Cavigioli, Carmine Tinelli, Michele Autelli, Maurizio Aricò, Gianluca Aimaretti and Ezio Ghigo

Departments of Pediatrics (M.M., F.C., M.A.), Biometry-Scientific Direction (C.T.), and Servizio Analisi Chimico Cliniche (M.A.), IRCCS Policlinico S. Matteo, University of Pavia, I-27100 Pavia; and Division of Endocrinology (G.A., E.G.), Department of Internal Medicine, University of Turin, 10126 Turin, Italy

Address all correspondence and requests for reprints to: Mohamad Maghnie, M.D., Ph.D., Department of Pediatrics, IRCCS Policlinico S. Matteo, Viale Golgi 2, 27100 Pavia, Italy. E-mail: . maghnie{at}smatteo.pv.it

Abstract

We evaluated the GH-releasing effect of GHRH plus arginine (ARG) in 36 patients (22 males and 14 females) with acquired GH deficiency including idiopathic inflammatory pituitary stalk thickness (n = 15), Langerhans cell histiocytosis (LCH) affecting the hypothalamic-pituitary area (n = 11), and craniopharyngioma (n = 10). All of the patients (mean age, 9.6 ± 3.1 yr; range, 5.6–20.8) showed GH response less than 10 µg/liter after 2 pharmacological stimuli and were tested with GHRH plus ARG at a mean age of 11.2 ± 4.1 yr. Twenty-nine patients had vasopressin deficiency, 10 had TSH deficiency, 8 had gonadotropin deficiency, and 4 had ACTH deficiency.

The median peak GH response to insulin test was 2.1 µg/liter (range, 1.1–2.9), whereas it was 1.5 µg/liter (range, 1.3–2.4) after ARG. The median peak GH response to insulin was significantly lower in the patients with craniopharyngioma (1.4 µg/liter; range, 0.8–1.7) than in the patients with idiopathic pituitary stalk thickness (2.2 µg/liter; range, 1.0–2.4) or with LCH (2.6 µg/liter; range 2.0–4.3, P = 0.02). The median peak GH response to ARG was significantly lower in the patients with idiopathic inflammatory pituitary stalk thickness (1.3 µg/liter; range, 0.8–1.8) than in those with craniopharyngioma (1.5 µg/liter; range, 1.1–1.6) or with LCH (2.8 µg/liter; range, 1.9–3.2, P = 0.00007).

The median peak GH response after GHRH plus ARG was significantly lower in the overall patient population (8.3 µg/liter; range, 4.4–28.4) than in the age-matched controls (49.8 µg/liter; range, 39.9–81.6, P < 0.00001). The median peak GH response was significantly lower in the patients with craniopharyngioma (4.6 µg/liter; range, 3.6–6.3) than in those with LCH (8.9 µg/liter; range, 4.4–28.4) or with idiopathic pituitary stalk thickness (12.6 µg/liter, range, 6.4–24, P = 0.07). Ten patients had a GH response of more than 20 µg/liter after GHRH plus ARG. There was a trend toward a decrease in peak GH response to GHRH plus ARG (r = -0.57, P = 0.06) as patient age increased. For cut-off values of 20 µg/liter, the sensitivity of GHRH plus ARG was 75% (95% CI, 57.8–87.9%) and the specificity was 96.4% (95% CI, 89.9–99.2%); whereas, for cut-off values of 24.2 µg/liter, sensitivity was 86.1% (95% CI, 70.5–95.3%), and specificity was 95.2% (95% CI, 88.2–98.7%). The median IGF-I level did not differ between the children with idiopathic pituitary stalk thickness (57 µg/liter; range, 46–68), those with LCH (55 µg/liter; range, 34–63), and those with craniopharyngioma (41 µg/liter; range, 39–49).

The present study confirmed the diagnostic potential of the GHRH-plus-ARG test in children with acquired GH deficiency caused by hypothalamic-pituitary lesion. It stimulates GH secretion to a greater extent in those patients with GH deficiency with primary involvement of the hypothalamic area, e.g. patients with idiopathic pituitary stalk thickness or LCH, than in those with both hypothalamic and pituitary lesion, as in craniopharyngioma. In some patients, the GHRH-plus-ARG test stimulates GH response to a so-called: normal value, suggesting that pituitary responsiveness to GHRH plus ARG may fail to recognize acquired GHD. Finally, the number of pituitary hormone deficits and the patient’s age affect the GH response to GHRH plus ARG.




This article has been cited by other articles:


Home page
Eur J EndocrinolHome page
G. Corneli, C. Di Somma, F. Prodam, J. Bellone, S. Bellone, V. Gasco, R. Baldelli, S. Rovere, H. J. Schneider, L. Gargantini, et al.
Cut-off limits of the GH response to GHRH plus arginine test and IGF-I levels for the diagnosis of GH deficiency in late adolescents and young adults
Eur. J. Endocrinol., December 1, 2007; 157(6): 701 - 708.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
N. di Iorgi, A. Secco, F. Napoli, C. Tinelli, A. Calcagno, N. Fratangeli, L. Ambrosini, A. Rossi, R. Lorini, and M. Maghnie
Deterioration of Growth Hormone (GH) Response and Anterior Pituitary Function in Young Adults with Childhood-Onset GH Deficiency and Ectopic Posterior Pituitary: A Two-Year Prospective Follow-Up Study
J. Clin. Endocrinol. Metab., October 1, 2007; 92(10): 3875 - 3884.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
J. Bjork, K. Link, and E. M. Erfurth
The Utility of the Growth Hormone (GH) Releasing Hormone-Arginine Test for Diagnosing GH Deficiency in Adults with Childhood Acute Lymphoblastic Leukemia Treated with Cranial Irradiation
J. Clin. Endocrinol. Metab., November 1, 2005; 90(11): 6048 - 6054.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
M. Maghnie, G. Aimaretti, S. Bellone, G. Bona, J. Bellone, R. Baldelli, C. de Sanctis, L. Gargantini, R. Gastaldi, L. Ghizzoni, et al.
Diagnosis of GH deficiency in the transition period: accuracy of insulin tolerance test and insulin-like growth factor-I measurement
Eur. J. Endocrinol., April 1, 2005; 152(4): 589 - 596.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
E. L. Germain-Lee, J. Groman, J. L. Crane, S. M. Jan de Beur, and M. A. Levine
Growth Hormone Deficiency in Pseudohypoparathyroidism Type 1a: Another Manifestation of Multihormone Resistance
J. Clin. Endocrinol. Metab., September 1, 2003; 88(9): 4059 - 4069.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
A. De Bellis, A. Bizzarro, M. Conte, S. Perrino, C. Coronella, S. Solimeno, A. M. Sinisi, L. A. Stile, G. Pisano, and A. Bellastella
Antipituitary Antibodies in Adults with Apparently Idiopathic Growth Hormone Deficiency and in Adults with Autoimmune Endocrine Diseases
J. Clin. Endocrinol. Metab., February 1, 2003; 88(2): 650 - 654.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2002 by The Endocrine Society